https://www.biopharmawatch.com/news/COSM/cosmos-health-ai-enabled-subscription-platform BiopharmaWatch en 2026-07-27T17:05:00.000Z Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels https://www.biopharmawatch.com/news/OLMA/betfirst-login-troubleshooting-netherlands BiopharmaWatch en 2026-07-27T16:53:33.000Z Betfirst Login Troubleshooting For Users In The Netherlands https://www.biopharmawatch.com/news/HCSG/pgp-welcomes-steven-grassa-managing-director BiopharmaWatch en 2026-07-27T16:10:00.000Z PGP Welcomes Steven Grassa as Managing Director to Deepen Healthcare Services Coverage https://www.biopharmawatch.com/news/CAPR/capricor-deramiocel-fda-advisory-meeting-update BiopharmaWatch en 2026-07-27T15:00:00.000Z Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel https://www.biopharmawatch.com/news/AVNS/american-industrial-partners-acquires-avanos-medical BiopharmaWatch en 2026-07-27T13:28:00.000Z American Industrial Partners Completes Acquisition of Avanos Medical, Inc. https://www.biopharmawatch.com/news/ACH/accendra-health-q2-2026-earnings-release-date BiopharmaWatch en 2026-07-27T13:15:00.000Z Accendra Health Announces Second Quarter 2026 Earnings Release Date and Conference Call https://www.biopharmawatch.com/news/CRIS/assurecare-curis-partner-rht-funding-infrastructure BiopharmaWatch en 2026-07-27T13:03:00.000Z AssureCare® and CURIS Partner to Ensure RHT Funding Builds Infrastructure That Outlasts the Program https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-ebola-ziare-d-mav-platform BiopharmaWatch en 2026-07-27T13:00:00.000Z Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-canaccord-genuity-conference-2026 BiopharmaWatch en 2026-07-27T12:32:00.000Z Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference https://www.biopharmawatch.com/news/ICCM/icecure-medical-choicestudy-breast-cancer BiopharmaWatch en 2026-07-27T12:32:00.000Z IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-ceo-appointment BiopharmaWatch en 2026-07-27T12:30:00.000Z Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-sonata-hcm-study-enrollment-completed BiopharmaWatch en 2026-07-27T12:30:00.000Z Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM) https://www.biopharmawatch.com/news/ENTX/entera-bio-private-placement-275-million BiopharmaWatch en 2026-07-27T12:30:00.000Z Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement https://www.biopharmawatch.com/news/SPRC/scisparc-targets-agentic-ai-market BiopharmaWatch en 2026-07-27T12:25:00.000Z SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity https://www.biopharmawatch.com/news/MDCX/medicus-pharma-fda-study-skinject-gorlin-syndrome BiopharmaWatch en 2026-07-27T12:17:00.000Z Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome https://www.biopharmawatch.com/news/VERU/veru-phase-2b-plateau-trial-enrollment-completed BiopharmaWatch en 2026-07-27T12:10:00.000Z Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss https://www.biopharmawatch.com/news/WAT/waters-launches-xevo-tq-absolute-xr-ivd-mass-spectrometer BiopharmaWatch en 2026-07-27T12:10:00.000Z Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-cypath-lung-clinical-framework BiopharmaWatch en 2026-07-27T12:08:00.000Z bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung https://www.biopharmawatch.com/news/PLUR/pluristyx-partners-regenerative-medicine-hepatocyte-manufacturing BiopharmaWatch en 2026-07-27T12:07:00.000Z Pluristyx Partners With Leading Regenerative Medicine and Aerospace Pioneers to Standardize Clinical-Grade Hepatocyte Manufacturing for Space and Earth Applications https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-appoints-adrian-quartel-cmo BiopharmaWatch en 2026-07-27T12:00:00.000Z Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer https://www.biopharmawatch.com/news/ATRC/atricure-participate-investor-conferences BiopharmaWatch en 2026-07-27T12:00:00.000Z AtriCure to Participate at Upcoming Investor Conferences https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-aacr-conference-2026 BiopharmaWatch en 2026-07-27T12:00:00.000Z Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-appoints-debra-zack-cmo BiopharmaWatch en 2026-07-27T12:00:00.000Z Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer https://www.biopharmawatch.com/news/HUMA/humacyte-fda-acceptance-ind-ctev-cabg BiopharmaWatch en 2026-07-27T12:00:00.000Z Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting https://www.biopharmawatch.com/news/FRNM/freenome-simplescreen-crc-fda-approval-abbott-commercialization BiopharmaWatch en 2026-07-27T12:00:00.000Z FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S. https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-pcrx-201-manufacturing-transition BiopharmaWatch en 2026-07-27T12:00:00.000Z Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process https://www.biopharmawatch.com/news/KYTX/kyverna-elevatebio-manufacturing-agreement-miv-cel BiopharmaWatch en 2026-07-27T12:00:00.000Z Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel https://www.biopharmawatch.com/news/FBIO/fortress-biotech-urica-therapeutics-crystalys-financing BiopharmaWatch en 2026-07-27T12:00:00.000Z Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing https://www.biopharmawatch.com/news/LH/labcorp-launches-marker-genetic-health-panel BiopharmaWatch en 2026-07-27T12:00:00.000Z Labcorp Launches Marker by Labcorp™ Genetic Health Panel, Expanding Consumer Access to Hereditary Genetic Risk Testing https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-appoints-michael-carrel-board BiopharmaWatch en 2026-07-27T12:00:00.000Z Inspire Medical Systems, Inc. Announces Appointment of Seasoned Medical Device Executive Michael H. Carrel to its Board of Directors https://www.biopharmawatch.com/news/CTMX/cytomx-appoints-charles-fuchs-board-directors BiopharmaWatch en 2026-07-27T12:00:00.000Z CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-phase-3-yosemite-study-zodasiran BiopharmaWatch en 2026-07-27T11:30:00.000Z Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-first-patient-dosed-teluride-008 BiopharmaWatch en 2026-07-27T11:30:00.000Z Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/GLAS/glass-house-brands-dea-compliance-advisor BiopharmaWatch en 2026-07-27T11:30:00.000Z Glass House Brands Retains Former DEA Compliance Executive to Advise on Interstate Commerce and Export Opportunities https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-purpose-health-ai-leadership BiopharmaWatch en 2026-07-27T11:10:00.000Z Healthcare Triangle Creates "Purpose Health" to Monetize AI Demand and Accelerate Shareholder Returns https://www.biopharmawatch.com/news/DTIL/precision-biosciences-leadership-changes-clinical-milestones BiopharmaWatch en 2026-07-27T11:01:00.000Z Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones https://www.biopharmawatch.com/news/GKOS/glaukos-preserflo-microshunt-enrollment-completion BiopharmaWatch en 2026-07-27T11:00:00.000Z Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt https://www.biopharmawatch.com/news/VYNE/yarrow-bioscience-merger-vyne-therapeutics-phase-2-trial BiopharmaWatch en 2026-07-27T11:00:00.000Z Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease https://www.biopharmawatch.com/news/GOSS/gossamer-bio-fda-update-seralutinib-reacquisition BiopharmaWatch en 2026-07-27T11:00:00.000Z Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update https://www.biopharmawatch.com/news/AZN/astrazeneca-h1-q2-2026-results BiopharmaWatch en 2026-07-27T11:00:00.000Z AstraZeneca results: H1 and Q2 2026 https://www.biopharmawatch.com/news/BHVN/biohaven-yale-avilar-trade-secret-verdict BiopharmaWatch en 2026-07-27T11:00:00.000Z Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-positive-results-phase-2-zephyr-trial BiopharmaWatch en 2026-07-27T11:00:00.000Z MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-australian-regulatory-clearance-cmp-002 BiopharmaWatch en 2026-07-27T11:00:00.000Z CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder https://www.biopharmawatch.com/news/NMRA/neumora-nmra-215-toxicology-results-clinical-advancement-2026 BiopharmaWatch en 2026-07-27T11:00:00.000Z Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026 https://www.biopharmawatch.com/news/VRXA/veraxa-biotech-advancement-vxa-222-program BiopharmaWatch en 2026-07-27T11:00:00.000Z VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb https://www.biopharmawatch.com/news/PMI/picard-medical-nyse-american-compliance-plan BiopharmaWatch en 2026-07-27T11:00:00.000Z Picard Medical Receives NYSE American Acceptance of Compliance Plan https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-07-27T11:00:00.000Z Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026 https://www.biopharmawatch.com/news/HROW/harrow-report-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-27T11:00:00.000Z Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026 https://www.biopharmawatch.com/news/OKYO/okyo-pharma-btig-biotechnology-conference-2026 BiopharmaWatch en 2026-07-27T11:00:00.000Z OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 https://www.biopharmawatch.com/news/TDOC/teladoc-health-canada-accreditation-award BiopharmaWatch en 2026-07-27T10:45:00.000Z Teladoc Health Canada Achieves Accreditation Canada Primer Award, Advancing Quality Standards for Virtual and Hybrid Care in Canada https://www.biopharmawatch.com/news/KURA/kura-oncology-darlifarnib-cabozantinib-ccrcc-results BiopharmaWatch en 2026-07-27T10:32:00.000Z Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026 https://www.biopharmawatch.com/news/ENSG/ensign-group-q2-2026-results BiopharmaWatch en 2026-07-27T10:04:00.000Z The Ensign Group Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-ide892-phase-1-2-expansion BiopharmaWatch en 2026-07-27T10:00:00.000Z IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers https://www.biopharmawatch.com/news/PFSA/profusa-management-changes-acquisition-term-sheet BiopharmaWatch en 2026-07-27T10:00:00.000Z Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company https://www.biopharmawatch.com/news/LEGN/legend-biotech-ceo-transition BiopharmaWatch en 2026-07-27T10:00:00.000Z Legend Biotech Announces CEO Transition https://www.biopharmawatch.com/news/OLMA/fatpirate-bonus-wagering-requirements-dutch-players BiopharmaWatch en 2026-07-27T09:28:51.000Z Fatpirate Bonus Wagering Requirements For Dutch Players https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-07-27 BiopharmaWatch en 2026-07-27T07:15:36.214Z Biotech Catalysts to Watch: Key Developments for 2026 and Beyond https://www.biopharmawatch.com/news/ARGX/argenx-acquires-forte-biosciences-immunology-pipeline BiopharmaWatch en 2026-07-27T05:07:00.000Z argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline https://www.biopharmawatch.com/news/FBRX/argenx-acquires-forte-biosciences-anti-cd122-antibody BiopharmaWatch en 2026-07-27T05:00:00.000Z argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-ceo-dajun-yang-power-list-2026 BiopharmaWatch en 2026-07-26T23:30:00.000Z Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 https://www.biopharmawatch.com/news/RXST/rxsight-inducement-grants-nasdaq-listing-rules BiopharmaWatch en 2026-07-26T20:00:00.000Z RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-chmp-recommendation-ubeslo-evlarco BiopharmaWatch en 2026-07-26T17:59:00.000Z NewAmsterdam Pharma und die Menarini Group erhalten positive Stellungnahme des CHMP mit der Empfehlung zur Erteilung einer Zulassung für Ubeslo® (Obicetrapib-Monotherapie) und Evlarco® (Festsatzkombination aus Obicetrapib und Ezetimib) https://www.biopharmawatch.com/news/OLMA/5gringos-registration-steps-norway BiopharmaWatch en 2026-07-26T16:13:06.000Z 5Gringos Registration Steps For Players In Norway https://www.biopharmawatch.com/news/OLMA/amazon-slots-registration-steps-belgian-players BiopharmaWatch en 2026-07-26T16:09:31.000Z Amazon Slots Registration Steps For Belgian Players https://www.biopharmawatch.com/news/OLMA/resolving-cashpot-login-issues-dutch-players BiopharmaWatch en 2026-07-26T15:38:54.000Z Resolving Cashpot Login Issues For Dutch Players https://www.biopharmawatch.com/news/OLMA/spinshouse-login-troubleshooting-netherlands-players BiopharmaWatch en 2026-07-26T15:32:46.000Z Spinshouse Login Troubleshooting For Netherlands Players https://www.biopharmawatch.com/news/OLMA/slots-eater-account-login-issues-guide BiopharmaWatch en 2026-07-26T14:24:15.000Z How To Fix SlotsEater Account Login And Access Issues https://www.biopharmawatch.com/news/OLMA/caxino-deposits-withdrawals-netherlands-payment-methods-fees BiopharmaWatch en 2026-07-26T14:00:02.000Z Caxino Deposits And Withdrawals In The Netherlands: Supported Payment Methods And Fees